Globus Medical (GMED) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Globus Medical stock $102, price $81.44, upside +24.9%, quality 66 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range $43.79 – $96.82 · fair‑value band $59.96 – $132.19 · the $81.44 price screens below the $101.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Globus Medical in your weekly email
Every Wednesday you see whether Globus Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Show moreShow less
The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.
It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems.
In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution.
Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Stock analysis
Globus Medical (GMED) currently trades at $81.44, while our model-based Fair Value estimate is $101.68, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $111.87 per share, and 11 of the 24 models we run sit above the $81.44 price.
Bear case: the Economic Profit group reads lowest at $33.09, and 13 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $59.96 (bear) to $132.19 (bull), the price of $81.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Globus Medical reported revenue of $2.9B in FY2025 versus $958M in FY2021, a compound +32.3%/yr. Reported net income was $538M in FY2025, compounding +37.8%/yr from FY2021.
Key figures
Market cap $11.3B Large · P/E ratio 20.9 · P/S ratio 3.58 · EPS (TTM) $3.90 · Net margin 17.0% · Return on equity 11.8% · Return on assets (EBIT) 6.9% · Operating margin 24.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 25%, GMED screens cheaper than that median.
Fair Value models
Bear$59.96Fair Value $101.68Bull$132.19
Price $81.44 · Upside +24.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.31 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 4 officers or directors sold shares worth $6.9M and none bought.
SaleAnn D RhoadsDirector2× since Nov 7, 2025: 15,000 shares, avg. $82.87$1.2MNov 4, 202610b5-1 plan
SaleJames R TobinDirector30,000 shares at $74.58$2.2MSep 15, 2026
SaleStephen T ZarrilliDirector2× since Nov 11, 2025: 50,000 shares, avg. $85.67$4.3MAug 18, 2026
SaleDavid D DavidarDirector2× since Nov 12, 2025: 50,000 shares, avg. $83.38$4.2MJun 5, 2026
SaleKelly HullerEVP, GC, Corporate Secretary3× since Nov 25, 2025: 37,500 shares, avg. $91.78$3.4MFeb 25, 202610b5-1 plan
SaleLeslie Norwalk VDirector2× since Dec 12, 2025: 6,000 shares, avg. $92.93$557,600Jan 8, 202610b5-1 plan
SaleKyle KlineSenior Vice President, CFO2× since Dec 1, 2025: 22,136 shares, avg. $91.80$2.0MJan 8, 202610b5-1 plan
Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+16.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
Start year 2020 (pandemic). Over 10 years: +18.4% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+21.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+21.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.22.2% vs 13.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 16%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +5.2% a year for the price and +3.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Globus Medical benefits from a debt-free balance sheet that funds R&D and supports share gains in spine and trauma solutions, yet thin public signals limit moat assessment amid potential margin pressure from robotics scaling.
Main risk: Competitors such as Stryker with its Mako system and Medtronic with Mazor could gain share in robotic spine and knee procedures, pressuring prices and margins on Globus implants and enabling technologies.
Bull case: By integrating acquired AI tools and patient-specific implants into its Excelsius ecosystem, Globus could strengthen hospital loyalty and shift toward higher-margin recurring revenue streams.
Bear case: Intensifying competition from established robotic platforms combined with regulatory constraints on its flagship system could erode market position and slow adoption of new technologies.
Globus Medical is gaining share in musculoskeletal solutions backed by more than sixty active development projects and a debt-free balance sheet that funds R&D and expansion. Core spine and trauma growth continues even as the company integrates acquisitions and advances its Excelsius ecosystem. Our models see it as undervalued, yet will pipeline momentum outweigh any margin pressure from scaling robotics and new technologies?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+24.9% · Top 25%
Profitability
Return on equity (12 months)11.8% · Top 25%
Return on assets10.1% · Top 25%
Net margin (12 months)17.0% · Top 25%
Operating margin (12 months)24.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)5.9% · Below median
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Globus Medical Fair Value". https://www.fairvalue-calculator.com/stock/GMED
Frequently asked questions
Is Globus Medical (GMED) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of $101.68 versus a price of $81.44, about +25% upside (undervalued).
What is the fair value of GMED?
Our model-based fair value for Globus Medical is $101.68 (as of Nov 3, 2026), built from audited fundamentals. The current price: $81.44.
What is the quality score of GMED?
Globus Medical has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Globus Medical (GMED)?
Our model-based price target is the fair value of $101.68 (as of Nov 3, 2026) from 24 valuation models. Cautious scenario $59.96, optimistic scenario $132.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Globus Medical stock forecast for 2026?
Our models put fair value at $101.68, about +25% upside versus a price of $81.44 (undervalued). Cautious scenario $59.96, optimistic scenario $132.19. The calculation is refreshed regularly with new filings.
What is the revenue of Globus Medical (GMED)?
Globus Medical reported trailing-twelve-month revenue of about $3.1B (latest available figure, as of Nov 3, 2026).
What growth is priced into Globus Medical (GMED)?
For today's price to be fair in a discounted-cash-flow model, Globus Medical would have to grow free cash flow by +7.7 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +30.1 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of GMED use?
Our models discount Globus Medical at 9.1 %: a base by market capitalisation (large), damped by beta 0.96, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Globus Medical that is +7.7 % per year a year over ten years, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Globus Medical (GMED) delivered so far?
Over the past 5 years revenue at Globus Medical grew +30.1 % a year. The price currently implies +7.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Globus Medical (GMED) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Globus Medical (+7.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Globus Medical (GMED)?
The free-cash-flow yield on the price is 5.23 %: that much free cash flow Globus Medical produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Globus Medical (GMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Globus Medical it is $101.68 per share (as of Nov 3, 2026), against a price of $81.44. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Globus Medical stock overvalued or undervalued in 2026?
As of Nov 3, 2026, GMED trades below its calculated fair value: price $81.44, fair value $101.68, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GMED?
No. The price is what the market pays today ($81.44); the fair value is what the company's own numbers justify ($101.68). For Globus Medical the two are $20.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Globus Medical worth?
The market values Globus Medical at about $11.3B (market capitalisation, as of Nov 3, 2026). Per share that is $81.44; our models calculate a fair value of $101.68 per share.
What do the bullish and bearish scenarios say about GMED?
Our models span a range for Globus Medical: cautious scenario $59.96, base $101.68, optimistic $132.19 per share (as of Nov 3, 2026, price $81.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GMED?
Globus Medical trades at a price-to-earnings ratio of 20.9 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $101.68 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), earnings ex one-offs: 37.2. Other multiples: PEG 1.7, P/B 2.5, P/S 3.6, EV/EBITDA 11.0.
What is the PEG ratio of GMED?
The PEG ratio of Globus Medical is 1.73 (P/E divided by earnings growth, as of Nov 3, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Globus Medical (GMED)?
Balance-sheet figures for Globus Medical (as of Nov 3, 2026): return on equity 11.8%, debt of 0.09 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is GMED from its 52-week high?
Globus Medical trades at $81.44, about 16% below its 52-week high of $96.82 and 32% above the low of $61.51 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $101.68 is for.
Which stocks are comparable to Globus Medical?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Globus Medical stock attractive at the current price?
The data as of Nov 3, 2026: price $81.44, calculated fair value $101.68 (+25%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GMED calculated?
We run Globus Medical through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $101.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Globus Medical currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Globus Medical (GMED)?
The closing price on Nov 5, 2026 was $81.44. Our model-based fair value is $101.68, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Globus Medical right now?
Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($59.96 to $132.19) leaves room in how you read the outcome.
Where does the earnings growth of Globus Medical (GMED) come from?
Earnings per share at Globus Medical grew +6.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +14.1 %, EBIT margin −10.3 %, tax rate +2.9 %, residual (interest, one-offs) +1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Globus Medical
How large is the market capitalisation of Globus Medical (GMED)?
The market capitalisation of Globus Medical is $11.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Globus Medical (GMED)?
The price-to-sales ratio of Globus Medical is 3.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Globus Medical (GMED)?
Earnings per share at Globus Medical are $3.90 (price ÷ EPS = P/E 20.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Globus Medical (GMED)?
The net margin of Globus Medical is 17.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Globus Medical (GMED)?
The return on equity (ROE) of Globus Medical is 11.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Globus Medical (GMED)?
On an EBIT basis the return on assets of Globus Medical is 6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Globus Medical (GMED)?
The operating margin of Globus Medical is 24.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Globus Medical (GMED)?
Revenue at Globus Medical is growing +5.9% versus a year earlier (3y avg +42.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Globus Medical (GMED)?
Earnings per share at Globus Medical are growing −26.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Globus Medical (GMED) hold?
Globus Medical holds more cash than debt, $408M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Globus Medical in the live analysis
One click puts Globus Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 3, 2026